Rhythm Pharmaceuticals jumps after Q1 revenue beat and new IMCIVREE obesity approvals
RYTM•Rhythm Pharmaceuticals shares rose after the company reported Q1 2026 results on May 5, 2026, with IMCIVREE net product revenue of $60.1 million and 150 patient starts. The update also highlighted recently expanded approvals for acquired hypothalamic obesity in the U.S. (FDA approval March 19, 2026) and Europe (European Commission authorization May 1, 2026).
1) What’s moving the stock today
Rhythm Pharmaceuticals (RYTM) is trading higher as investors digest the company’s first-quarter 2026 earnings update released May 5, 2026, which emphasized faster commercialization momentum for IMCIVREE (setmelanotide). The report flagged net product revenue of $60.1 million and 150 patient starts in the quarter, reinforcing the view that the newly expanded hypothalamic obesity (HO) label is translating into early demand and a broader commercial runway. (stocktitan.net)
